DE69921178D1 - Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit - Google Patents

Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit

Info

Publication number
DE69921178D1
DE69921178D1 DE1999621178 DE69921178T DE69921178D1 DE 69921178 D1 DE69921178 D1 DE 69921178D1 DE 1999621178 DE1999621178 DE 1999621178 DE 69921178 T DE69921178 T DE 69921178T DE 69921178 D1 DE69921178 D1 DE 69921178D1
Authority
DE
Germany
Prior art keywords
nicotine
hapten
conjugates
antibodies
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1999621178
Other languages
English (en)
Other versions
DE69921178T2 (de
Inventor
Sofiane Ennifar
Ibrahim Fattom
B Naso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nabi Biopharmaceuticals Inc
Original Assignee
Nabi Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69921178(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabi Biopharmaceuticals Inc filed Critical Nabi Biopharmaceuticals Inc
Application granted granted Critical
Publication of DE69921178D1 publication Critical patent/DE69921178D1/de
Publication of DE69921178T2 publication Critical patent/DE69921178T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
DE69921178T 1998-12-01 1999-12-01 Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit Expired - Lifetime DE69921178T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction
US201800 1998-12-01
PCT/US1999/028272 WO2000032239A1 (en) 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Publications (2)

Publication Number Publication Date
DE69921178D1 true DE69921178D1 (de) 2004-11-18
DE69921178T2 DE69921178T2 (de) 2005-11-17

Family

ID=22747358

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921178T Expired - Lifetime DE69921178T2 (de) 1998-12-01 1999-12-01 Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit

Country Status (26)

Country Link
US (7) US6232082B1 (de)
EP (3) EP2324855A1 (de)
JP (2) JP4971542B2 (de)
KR (1) KR100656836B1 (de)
CN (2) CN100586481C (de)
AT (1) ATE279211T1 (de)
AU (1) AU763001B2 (de)
BR (1) BR9915852A (de)
CA (1) CA2352765C (de)
DE (1) DE69921178T2 (de)
DK (1) DK1135166T3 (de)
EA (1) EA004956B1 (de)
ES (1) ES2229800T3 (de)
HK (3) HK1042428B (de)
HU (1) HUP0104365A3 (de)
IL (2) IL143474A0 (de)
ME (1) MEP34208A (de)
MX (1) MXPA01005511A (de)
NO (1) NO331998B1 (de)
NZ (1) NZ512103A (de)
PL (1) PL199253B1 (de)
PT (1) PT1135166E (de)
RS (1) RS51273B (de)
TR (1) TR200102411T2 (de)
WO (1) WO2000032239A1 (de)
ZA (1) ZA200104477B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2002058635A2 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
WO2003082329A2 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
EP1523334A2 (de) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-träger-konjugate und ihre verwendung
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
DK3473251T3 (da) * 2002-12-20 2024-01-22 Niconovum Ab Nikotin-cellulose-kombination
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006091796A2 (en) * 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2007064478A2 (en) * 2005-11-28 2007-06-07 Nabi Biopharmaceuticals Method for making nicotine hapten
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
EP1849780A1 (de) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Impfstoff gegen Nikotinsucht
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
US8367113B2 (en) * 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
EP2065398A1 (de) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Humane, monoklonale, nikotinspezifische Antikörper
JP2011504893A (ja) * 2007-11-29 2011-02-17 サイトス バイオテクノロジー アーゲー ヒト・モノクローナル・ニコチン特異的抗体
CN102056624A (zh) * 2008-06-04 2011-05-11 康奈尔大学 用于防治成瘾的疫苗
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
CA2727617A1 (en) * 2008-06-13 2009-12-17 Nabi Biopharmaceuticals Smoking cessation kit and method
MX2011001373A (es) * 2008-08-08 2011-03-15 Novartis Ag Proceso para la preparacion de haptenos basados en nicotina.
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
CN102333538B (zh) 2008-12-09 2014-01-15 科勒制药集团有限公司 免疫刺激性寡核苷酸
US20110064750A1 (en) * 2009-07-31 2011-03-17 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
IN2012DN02589A (de) * 2009-08-26 2015-08-28 Selecta Biosciences Inc
US20120225087A1 (en) * 2009-09-14 2012-09-06 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
JP6367554B2 (ja) 2010-05-26 2018-08-01 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． アジュバント化合成ナノキャリアの投与量選択
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US20140039063A1 (en) * 2011-01-04 2014-02-06 National Jewish Health Leukotrienes and asthma exacerbation risk
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
WO2013154744A1 (en) * 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) * 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
US20170107275A1 (en) * 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
WO2016116477A1 (en) * 2015-01-20 2016-07-28 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
SG11201911930SA (en) 2017-06-11 2020-01-30 Molecular Express Inc Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN111432883A (zh) 2017-08-15 2020-07-17 安蒂多特疗法公司 新型烟碱结合抗体
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US11073296B2 (en) 2018-03-09 2021-07-27 Scot Matthew Duncan High efficiency dehumidification system (HEDS)
CN112512549A (zh) 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) * 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
AU5444386A (en) 1985-03-08 1986-09-11 Baylor College Of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal)
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
DE3884731D1 (de) 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (de) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoklonaler Antikörper gegen Morphin, Bereitung von monoklonalen Antikörpern, Testsatz und Verfahren zur Bestimmung von Morphin
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (de) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
DE69332637T2 (de) 1993-03-04 2003-10-23 Matsushita Electric Ind Co Ltd Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
EP0756629A1 (de) 1994-04-08 1997-02-05 Immunologic Pharmaceutical Corporation Pharmazeutische zusammensetzungen zur behandlung von allergiefür japanische zederpollen
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
EP0814843B1 (de) 1995-03-31 2003-11-26 Xenova Research Limited Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2303775A1 (en) * 1997-09-19 1999-03-25 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
US7247502B2 (en) 2007-07-24
DE69921178T2 (de) 2005-11-17
NZ512103A (en) 2003-09-26
CN1220521C (zh) 2005-09-28
WO2000032239A9 (en) 2002-08-22
NO20012589L (no) 2001-07-20
EP1135166B9 (de) 2005-02-02
MXPA01005511A (es) 2004-08-19
ES2229800T3 (es) 2005-04-16
US20080026000A1 (en) 2008-01-31
PL349012A1 (en) 2002-06-17
JP4971542B2 (ja) 2012-07-11
HK1043061A1 (en) 2002-09-06
PL199253B1 (pl) 2008-08-29
EP1135166A1 (de) 2001-09-26
HUP0104365A2 (hu) 2002-04-29
CA2352765C (en) 2011-02-15
US6773891B2 (en) 2004-08-10
ZA200104477B (en) 2002-01-16
US20050136047A1 (en) 2005-06-23
MEP34208A (en) 2011-02-10
AU2033500A (en) 2000-06-19
JP2002531421A (ja) 2002-09-24
US8026109B2 (en) 2011-09-27
HK1091415A1 (en) 2007-01-19
KR20010090854A (ko) 2001-10-19
US6232082B1 (en) 2001-05-15
CN1768861A (zh) 2006-05-10
DK1135166T3 (da) 2005-02-14
US7776620B2 (en) 2010-08-17
US20110002957A1 (en) 2011-01-06
EP1135166B1 (de) 2004-10-13
IL143474A0 (en) 2002-04-21
HUP0104365A3 (en) 2002-05-28
EP1512414A1 (de) 2005-03-09
US6518031B2 (en) 2003-02-11
CA2352765A1 (en) 2000-06-08
HK1042428A1 (en) 2002-08-16
IL143474A (en) 2006-06-11
US20110217320A1 (en) 2011-09-08
AU763001B2 (en) 2003-07-10
WO2000032239A1 (en) 2000-06-08
US20030165950A1 (en) 2003-09-04
CN100586481C (zh) 2010-02-03
RS51273B (sr) 2010-12-31
HK1043061B (zh) 2006-07-07
BR9915852A (pt) 2004-06-29
KR100656836B1 (ko) 2006-12-12
JP2011079849A (ja) 2011-04-21
ATE279211T1 (de) 2004-10-15
TR200102411T2 (tr) 2002-01-21
NO331998B1 (no) 2012-05-21
NO20012589D0 (no) 2001-05-25
HK1042428B (zh) 2005-07-29
EA004956B1 (ru) 2004-10-28
US20020004208A1 (en) 2002-01-10
EP2324855A1 (de) 2011-05-25
PT1135166E (pt) 2005-01-31
CN1329508A (zh) 2002-01-02
EA200100610A1 (ru) 2002-04-25
YU39601A (sh) 2003-10-31

Similar Documents

Publication Publication Date Title
DE69921178D1 (de) Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit
BR9711580A (pt) Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes
NO20012409D0 (no) Anvendelse av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, oglegemiddel erholdt derved
ATE316786T1 (de) Behandlung von mukositis
NO975555D0 (no) Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein
DE69232263T2 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
DK1329226T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
EP1782837A3 (de) Hapten-Träger-Konjugate zur Anwendung in der Drogenmissbrauchstherapie (Nikotin)
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
UA36465A (uk) Спосіб ушивання глибоких і нешироких ран та голка для його здійснення

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN